Fei Meirong, Shen Lingnv, Ding Xiuqin, Li Guoduan, You Jingyang
Meirong Fei Department of Gynaecology and Obstetrics, Huzhou Nanxun District People's Hospital, Huzhou, Zhejiang Province 313009, P.R. China.
Lingnv Shen Department of Gynaecology and Obstetrics, Huzhou Nanxun District People's Hospital, Huzhou, Zhejiang Province 313009, P.R. China.
Pak J Med Sci. 2024 Nov;40(10):2400-2404. doi: 10.12669/pjms.40.10.9724.
To explore the impact of levothyroxine (L-T4) administration at different time points on pregnancy outcomes and offspring development in patients with subclinical hypothyroidism (SCH).
In this retrospective study, medical records of 107 patients with SCH treated in Huzhou Nanxun District People's Hospital from February 2021 to March 2023 were retrospectively reviewed. Of them, 55 patients received treatment before eight gestational weeks (Early group), and 52 patients received treatment after eight gestational weeks (Mid group). Levels of thyroid function indicators, occurrence of adverse pregnancy outcomes, occurrence of adverse reactions, and development of offspring before and after the treatment were compared.
After the treatment, the thyroid function indicators in both groups improved compared to before treatment, and the improvement in the Early group was significantly better than that in the Mid group (<0.05). The incidence of adverse pregnancy outcomes in the early group (5.45%) was lower than that in the mid group (19.23%) (<0.05). There was no significant difference in the incidence of adverse reactions between the groups (>0.05). The scores of fine motor, gross motor, language, personal-social behavior, and adaptability in offspring of patients the Early group were higher than those of the mid group (<0.05).
Early administration of L-T4 is safe and can effectively improve thyroid function in SCH patients, reduce adverse pregnancy outcomes, and ensure growth and development of offspring.
探讨亚临床甲状腺功能减退症(SCH)患者在不同时间点给予左甲状腺素(L-T4)对妊娠结局及子代发育的影响。
本回顾性研究回顾性分析了2021年2月至2023年3月在湖州市南浔区人民医院接受治疗的107例SCH患者的病历。其中,55例患者在妊娠8周前接受治疗(早期组),52例患者在妊娠8周后接受治疗(中期组)。比较治疗前后甲状腺功能指标水平、不良妊娠结局的发生情况、不良反应的发生情况及子代发育情况。
治疗后,两组甲状腺功能指标均较治疗前有所改善,且早期组改善明显优于中期组(<0.05)。早期组不良妊娠结局发生率(5.45%)低于中期组(19.23%)(<0.05)。两组不良反应发生率比较,差异无统计学意义(>0.05)。早期组患者子代的精细运动、大运动、语言、个人-社会行为及适应性得分均高于中期组(<0.05)。
早期给予L-T4安全有效,可改善SCH患者甲状腺功能,降低不良妊娠结局,保障子代生长发育。